Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine (TACTIC): a Randomised, Double-blinded, Placebo-controlled, Multicentric Trial
Beijing Anzhen Hospital
6,574 participants
Sep 2, 2024
INTERVENTIONAL
Conditions
Summary
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06215989